Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly was second to the lucrative GLP-1 market for diabetes and obesity following its chief metabolic medicine rival Novo ...
Senator Ron Wyden (D-Oregon) recently bought shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 21st, the Senator disclosed that they had bought between $50,001 and $100,000 ...
Eli Lilly and Company (NYSE: LLY) will participate in TD Cowen's 45th Annual Health Care Conference on March 4, 2025. Jake Van Naarden, executive vice president and president, Lilly Oncology ...
Citi analyst Geoff Meacham reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $1,190.00. The ...
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50 ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...